Page 34 - Read Online

Page 10 of 11 Marchand-Adam et al. Rare Dis Orphan Drugs J 2023;2:3 https://dx.doi.org/10.20517/rdodj.2022.24

human macrophages. J Exp Med 2000;192:789-99. DOI PubMed PMC
22. Brömme D, Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular
cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler 1995;376:379-384. DOI PubMed
23. Quintanilla-Dieck MJ, Codriansky K, Keady M, Bhawan J, Rünger TM. Expression and regulation of cathepsin K in skin fibroblasts.
Exp Dermatol 2009;18:596-602. DOI PubMed
24. Friedrichs B, Tepel C, Reinheckel T, et al. Thyroid functions of mouse cathepsins B, K, and L. J Clin Invest 2003;111:1733-45. DOI
PubMed PMC
25. Tepel C, Brömme D, Herzog V, Brix K. Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in
extracellular proteolysis of thyroglobulin. J Cell Sci 2000;113 Pt 24:4487-98. DOI PubMed
26. Bühling F, Waldburg N, Reisenauer A, et al. Lysosomal cysteine proteases in the lung: role in protein processing and
immunoregulation. Eur Respir J 2004;23:620-628. DOI PubMed
27. Zhang D, Leung N, Weber E, Saftig P, Brömme D. The effect of cathepsin K deficiency on airway development and TGF-β1
degradation. Respir Res 2011;12:72. DOI PubMed PMC
28. Turk B, Turk D, Turk V. Protease signalling: the cutting edge. EMBO J 2012;31:1630-43. DOI PubMed PMC
29. Chen H, Wang J, Xiang MX, et al. Cathepsin S-mediated fibroblast trans-differentiation contributes to left ventricular remodelling
after myocardial infarction. Cardiovasc Res 2013;100:84-94. DOI PubMed PMC
30. Yue X, Piao L, Wang H, et al. Cathepsin K deficiency prevented kidney damage and dysfunction in response to 5/6 nephrectomy
injury in mice with or without chronic stress. Hypertension 2022;79:1713-23. DOI PubMed PMC
31. Zhang X, Zhou Y, Yu X, et al. Differential roles of cysteinyl cathepsins in tgf-β signaling and tissue fibrosis. iScience 2019;19:607-22.
DOI PubMed PMC
32. Lalmanach G, Saidi A, Marchand-Adam S, Lecaille F, Kasabova M. Cysteine cathepsins and cystatins: from ancillary tasks to
prominent status in lung diseases. Biol Chem 2015;396:111-30. DOI PubMed
33. Kasabova M, Joulin-Giet A, Lecaille F, et al. Regulation of TGF-β1-driven differentiation of human lung fibroblasts: emerging roles of
cathepsin B and cystatin C. J Biol Chem 2014;289:16239-51. DOI PubMed PMC
34. Biasizzo M, Javoršek U, Vidak E, Zarić M, Turk B. Cysteine cathepsins: a long and winding road towards clinics. Mol Aspects Med
2022;88:101150. DOI PubMed
35. Henriksen K, Thudium CS, Christiansen C, Karsdal MA. Novel targets for the prevention of osteoporosis - lessons learned from
studies of metabolic bone disorders. Expert Opin Ther Targets 2015;19:1575-84. DOI PubMed
36. Wen X, Yi LZ, Liu F, Wei JH, Xue Y. The role of cathepsin K in oral and maxillofacial disorders. Oral Dis 2016;22:109-15. DOI
PubMed
37. Xue Y, Wang L, Xia D, et al. Dental Abnormalities Caused by Novel Compound Heterozygous CTSK Mutations. J Dent Res
2015;94:674-81. DOI PubMed PMC
38. Zhang Y, Ji D, Li L, Yang S, Zhang H, Duan X. ClC-7 Regulates the pattern and early development of craniofacial bone and tooth.
Theranostics 2019;9:1387-400. DOI PubMed PMC
39. McClung MR, O'Donoghue ML, Papapoulos SE, et al; LOFT Investigators. Odanacatib for the treatment of postmenopausal
osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. Lancet
Diabetes Endocrinol 2019;7:899-911. DOI PubMed
40. Panwar P, Law S, Jamroz A, et al. Tanshinones that selectively block the collagenase activity of cathepsin K provide a novel class of
ectosteric antiresorptive agents for bone. Br J Pharmacol 2018;175:902-23. DOI PubMed PMC
41. Panwar P, Xue L, Søe K, et al. An ectosteric inhibitor of cathepsin K inhibits bone resorption in ovariectomized mice. J Bone Miner
Res 2017;32:2415-30. DOI PubMed
42. Yang YS, Xie J, Chaugule S, et al. Bone-Targeting AAV-mediated gene silencing in osteoclasts for osteoporosis therapy. Mol Ther
Methods Clin Dev 2020;17:922-35. DOI PubMed PMC
43. Cottin V, Archer F, Khouatra C, Lazor R, Cordier JF. [Lymphangioleiomyomatosis]. Presse Med 2010;39:116-25. DOI PubMed
44. Johnson SR, Cordier JF, Lazor R, et al; Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the
diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010;35:14-26. DOI PubMed
45. Harknett EC, Chang WY, Byrnes S, et al. Use of variability in national and regional data to estimate the prevalence of
lymphangioleiomyomatosis. QJM 2011;104:971-9. DOI PubMed
46. Henske EP, McCormack FX. Lymphangioleiomyomatosis - a wolf in sheep’s clothing. J Clin Invest 2012;122:3807-16. DOI PubMed
PMC
47. Taveira-DaSilva AM, Moss J. Epidemiology, pathogenesis and diagnosis of lymphangioleiomyomatosis. Expert Opin Orphan Drugs
2016;4:369-78. DOI PubMed PMC
48. Ruiz de Garibay G, Herranz C, Llorente A, et al. Lymphangioleiomyomatosis biomarkers linked to lung metastatic potential and cell
stemness. PLoS One 2015;10:e0132546. DOI PubMed PMC
49. Gown AM, Vogel AM, Hoak D, et al. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of
melanocytes. Am J Pathol 1986;123:195-203. PubMed PMC
50. Matsumoto Y, Horiba K, Usuki J, Chu SC, Ferrans VJ, Moss J. Markers of cell proliferation and expression of melanosomal antigen in
lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 1999;21:327-36. DOI PubMed
51. Young L, Lee HS, Inoue Y, et al; MILES Trial Group. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis